Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

King Restatement Will Boost 2004 Revenue, Income But Hurt Prior Year Results

This article was originally published in The Pink Sheet Daily

Executive Summary

The company says it is waiting to hear from Mylan on whether the firms' merger agreement will be terminated as a result of the restatement. King continues to evaluate whether financial results prior to 2002 will require restatement.

You may also be interested in...



King Inventory Work-Down Plan Goal Is 1.5 Months Of On-Hand Product

Amendments to inventory management agreements with wholesalers are aimed at reducing levels to 1.5 months by the end of March. Work-down announcement accompanies King’s restatement of financials; Mylan deal remains up in the air with one week to go before walk-away date.

King Inventory Work-Down Plan Goal Is 1.5 Months Of On-Hand Product

Amendments to inventory management agreements with wholesalers are aimed at reducing levels to 1.5 months by the end of March. Work-down announcement accompanies King’s restatement of financials; Mylan deal remains up in the air with one week to go before walk-away date.

Mylan Unlikely To Crown King: $3.8 Bil. Bid In Jeopardy Over Restatement

Mylan does not believe it has enough time to review King’s financial restatement and “other matters” before the Feb. 28 deadline for completing the merger. However, the company left open the possibility it could renegotiate the terms of the original acquisition agreement.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS058558

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel